Vitamin B6 Modulates NK Cell Metabolism in Pancreatic Cancer
维生素 B6 调节胰腺癌 NK 细胞代谢
基本信息
- 批准号:10568565
- 负责人:
- 金额:$ 39.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-05 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:Activated Natural Killer CellAdenocarcinoma CellAdoptive TransferAllogenicAnabolismAntitumor ResponseAttenuatedBiological AssayBloodCancer EtiologyCarbonCell DegranulationCell ProliferationCell SurvivalCell TherapyCell physiologyCellsCellular Metabolic ProcessCellular immunotherapyCessation of lifeCirculationCoculture TechniquesCoenzyme ADataDependenceDevelopmentDietExclusionExhibitsFrequenciesFunctional disorderGlucoseGlutamineGlycineGlycogenGlycogen PhosphorylaseGlycogenolysis InductionGlycolysisGrowthHydroxymethyltransferasesHypoxiaImmuneImmunotherapyImpairmentIncidenceInfusion proceduresInterferon Type IIKiller CellsKineticsKnock-outKynurenineLabelLinkMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMetabolicMetabolic PathwayMetabolismModelingMonitorMusNADPNatural Killer CellsNucleotidesNutrientOrganoidsPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPhasePhenotypePlayProductionPrognostic FactorProliferatingResearch PersonnelRiskRoleSerineStarvationSupplementationSurvival RateT-LymphocyteTherapeuticTherapeutic StudiesTreatment EfficacyTryptophanTumor BurdenVitamin B 6 DeficiencyVitamin B6Vitamin B6 Metabolism Pathwayattenuationcancer cellchemotherapycofactorcytotoxicexhaustexhaustionglycogenolysisimmune functionimprovedinhibitorknock-downmouse modelneoplastic cellnovel therapeuticspancreatic cancer cellspancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpancreatic neoplasmpatient derived xenograft modelrapid growthresponsestandard of caresuccesstooltumortumor growthtumor hypoxiatumor microenvironmenttumor progressiontumor-immune system interactionstumorigenesis
项目摘要
Project Summary: The poor survival rates in pancreatic ductal adenocarcinoma patients are in part due to poor
response to existing therapies. Thus, there is an urgent need to develop novel therapies. NK cell-based therapies
present a promising option because NK cells primarily target tumor cells through direct killing or IFN-gamma
production and are not dependent on MHC expression. However, in the tumor microenvironment, NK cells
directly compete with tumor cells for nutrients to maintain basal cellular metabolism. Of note, cellular metabolic
pathways are closely linked with the effector response of NK cells. Tumor-educated NK cells demonstrate
increased glycolysis, which potentiates their cytotoxic activity. However, the complete spectrum of metabolic
reprogramming in NK cells is not fully understood. Pancreatic tumors are highly glycolytic. The tumor cells exhibit
constant high demand for glucose or glutamine to fuel the anabolic needs and exhaust the essential nutrients in
the tumor microenvironment milieu. Nutrient starvation triggers metabolic alterations to support proliferation and
the aggressive phenotype of pancreatic tumors. Hence, the pancreatic tumor microenvironment displays nutrient
paucity, which restricts the metabolic flux in NK cells. Our preliminary data suggest the scarcity of vitamin B6 in
NK-tumor cell co-cultures becomes a limiting factor for the anti-tumor response of NK cells against pancreatic
tumor cells and organoids. Furthermore, vitamin B6 paucity and glucose-limitation induce metabolic rewiring in
NK cells to sustain glycolysis and downstream metabolic pathways. Of note, tumor progression causes a
systemic imbalance of vitamin B6. We observed a significant reduction in systemic vitamin B6 metabolites in
PDAC patients. Moreover, we demonstrate that pancreatic tumor cells display increased metabolic flux and
dependence on metabolic pathways that are dispensable for NK cells, providing a metabolic vulnerability that
can be targeted in combination with vitamin B6 supplementation. Taken together, we posit that pancreatic tumor
cells exhaust vitamin B6 in the tumor microenvironment milieu, impacting cellular metabolism and inducing NK
cell dysfunction. We will examine (Specific Aim 1) the metabolic pathways that favor tumor cell-mediated vitamin
B6 exhaustion in the PDAC TME milieu to sustain tumor cell proliferation under nutrient-limiting conditions. In
Specific Aim 2, we will investigate the functional significance of vitamin B6-induced metabolic remodeling in
NKs that regulate the anti-tumor response of NK cells in 2D cultures, organoids, and orthotopic mouse models.
We will also examine the therapeutic potential of targeting the selective metabolic dependencies of tumor cells,
in combination with vitamin B6 supplementation, in the context of nutrient limitation in the tumor
microenvironment in orthotopic and patient-derived xenograft models (Specific Aim 3). Overall, our study will
investigate the metabolic competition between pancreatic cancer cells and NK cells for understanding the
selective metabolic vulnerabilities for developing robust NK-based therapies in the long run.
项目摘要:胰腺导管腺癌患者的生存率较低,部分原因在于较差的治疗
对现有疗法的反应。因此,迫切需要开发新的疗法。基于 NK 细胞的疗法
提供了一个有前途的选择,因为 NK 细胞主要通过直接杀伤或 IFN-γ 来靶向肿瘤细胞
产生且不依赖于 MHC 表达。然而,在肿瘤微环境中,NK细胞
直接与肿瘤细胞竞争营养物质,维持基础细胞代谢。值得注意的是,细胞代谢
通路与 NK 细胞的效应反应密切相关。肿瘤培养的 NK 细胞证明
糖酵解增加,从而增强其细胞毒活性。然而,完整的代谢谱
NK 细胞的重编程尚不完全清楚。胰腺肿瘤是高度糖酵解的。肿瘤细胞表现出
对葡萄糖或谷氨酰胺的持续高需求来满足合成代谢的需要并耗尽体内的必需营养素
肿瘤微环境。营养饥饿会引发代谢改变以支持增殖和
胰腺肿瘤的侵袭性表型。因此,胰腺肿瘤微环境显示营养
缺乏,限制了 NK 细胞的代谢通量。我们的初步数据表明,维生素 B6 缺乏
NK-肿瘤细胞共培养成为 NK 细胞抗胰腺肿瘤反应的限制因素
肿瘤细胞和类器官。此外,维生素 B6 缺乏和葡萄糖限制会导致代谢重新布线
NK 细胞维持糖酵解和下游代谢途径。值得注意的是,肿瘤进展会导致
维生素B6的全身失衡。我们观察到全身维生素 B6 代谢物显着减少
PDAC 患者。此外,我们证明胰腺肿瘤细胞表现出增加的代谢通量和
对 NK 细胞来说可有可无的代谢途径的依赖,提供了代谢脆弱性
可以有针对性地结合维生素B6补充。综上所述,我们假设胰腺肿瘤
细胞耗尽肿瘤微环境中的维生素B6,影响细胞代谢并诱导NK
细胞功能障碍。我们将检查(具体目标 1)有利于肿瘤细胞介导的维生素的代谢途径
PDAC TME 环境中 B6 耗尽以在营养限制条件下维持肿瘤细胞增殖。在
具体目标 2,我们将研究维生素 B6 诱导的代谢重塑的功能意义
NK 在 2D 培养物、类器官和原位小鼠模型中调节 NK 细胞的抗肿瘤反应。
我们还将研究针对肿瘤细胞选择性代谢依赖性的治疗潜力,
在肿瘤营养有限的情况下,结合维生素 B6 补充剂
原位和患者来源的异种移植模型中的微环境(具体目标 3)。总的来说,我们的研究将
研究胰腺癌细胞和 NK 细胞之间的代谢竞争,以了解
从长远来看,选择性代谢脆弱性有助于开发基于 NK 的强大疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kamiya Mehla其他文献
Kamiya Mehla的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
- 批准号:
449570 - 财政年份:2020
- 资助金额:
$ 39.86万 - 项目类别:
Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺腺癌细胞系分析癌症转移和侵袭机制。
- 批准号:
16K10689 - 财政年份:2016
- 资助金额:
$ 39.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
- 批准号:
26460441 - 财政年份:2014
- 资助金额:
$ 39.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
- 批准号:
25860540 - 财政年份:2013
- 资助金额:
$ 39.86万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
- 批准号:
25461969 - 财政年份:2013
- 资助金额:
$ 39.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
- 批准号:
22791532 - 财政年份:2010
- 资助金额:
$ 39.86万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
- 批准号:
8164743 - 财政年份:2010
- 资助金额:
$ 39.86万 - 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
- 批准号:
19790127 - 财政年份:2007
- 资助金额:
$ 39.86万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
- 批准号:
6972483 - 财政年份:2004
- 资助金额:
$ 39.86万 - 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
- 批准号:
15590831 - 财政年份:2003
- 资助金额:
$ 39.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




